|
|
|
|
|
|
|
|
|
17.09.25 - 09:18
|
Forvia successfully prices USD500 Million of senior notes due 2033 and further diversifies its investor base (GlobeNewswire EN)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1993, AS AMENDED (THE “SECURITIES ACT”)) OR ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE US VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT....
|
|
|
17.09.25 - 09:15
|
Major shareholder announcement (GlobeNewswire EN)
|
|
|
In accordance with section 30 of the Capital Markets Act, Pandora A/S hereby announces that Parvus Asset Management Jersey Limited has notified the company that it now holds 8,096,877 shares, corresponding to 10.25% of the total voting rights and share capital (previously 7.68%)....
|
|
|
|
|
|
|
17.09.25 - 08:57
|
Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER (GlobeNewswire EN)
|
|
|
AecorBio Inc., formerly known as HBC Immunology Inc, has successfully completed a further equity financing round of $1.5m from existing and new investors at a company valuation of $30 million. This funding will enable AecorBio to complete the investigational work of its lead peptide candidate FT-002a, in advanced prostate cancer, to enable an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2026. Filing the IND will represent a critical milestone, paving the way for AecorBio to transition FT-002a into clinical development, as a co-therapy in the management of advanced prostate cancer....
|
|
|
|
|
17.09.25 - 08:33
|
Kaldvik AS – Mandatory notification of trade (GlobeNewswire EN)
|
|
|
Frøya, 17 September 2025: In connection with issuance of new shares in Kaldvik AS ("Kaldvik" or the "Company") as announced on 17 September 2025, Hege Dahl, a primary insider of the Company, and Larren Invest AS and AQON AS, being close associates to a primary insider of Kaldvik, have completed transactions in the Company's shares as further specified in the attached notifications of trading....
|
|
|
|
|
|
|
|
|
|
|
|
|
17.09.25 - 08:03
|
Kaldvik AS – Final results of the subsequent offering (GlobeNewswire EN)
|
|
|
Frøya, 17 September 2025: Reference is made to the stock exchange announcements by Kaldvik AS ("Kaldvik" or the "Company") on 29 August 2025 regarding the subsequent offering of up to 4,300,000 new shares in the Company ("Offer Shares"), each with a nominal value of NOK 0.10, at a subscription price of NOK 14 per Offer Share (the "Subsequent Offering") and on 16 September 2025 regarding that day being the last day of the subscription period in the Subsequent Offering....
|
|
|
17.09.25 - 08:03
|
NBPE - Transaction in Own Shares (GlobeNewswire EN)
|
|
|
THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
